Proteome Sciences

  • was founded in 1994 and has over 25 years of experience; our proteomic services being fully aligned to your drug development pipeline.
  • invented, developed and now exclusively manufacture TMT 11-plex and newer TMTpro 18-plex and more recently TMTpro 35-plex isobaric tags. These are supplied to other Mass Spectrometer users globally via our distribution partner ThermoFisher as part of their Mass Spectrometry consumable range.
  • is a specialised Contract Research Organisation (CRO) offering a full suite of Mass Spectrometric based protein discovery and detection tools on an outsourced client driven basis.
  • has worked with the majority of the top biopharma organisation globally and are ideally suited become your proteomic analysis partner.
  • handles all sample types including biological fluids and tissue from a variety of animal and plant sources.
  • covers the full needs from research and clinical via Discovery and Targeted workflows utilising Thermo Fisher Orbitrap (Ascend, Exploris 480 and Fusions), and TSQ Vantage triple quad mass spectrometers depending on the application.
  • works under ISO 9001:2015 for Discovery based Applications and Good Clinical Laboratory Practice (GCLP) for Targeted Assays as required.
  • offers a complete CRO Proteomic Discovery and Targeted based analytical service …
    • incoming sample QC check
    • sample preparation
    • full proteome characterisation,
    • dedicated bioinformatics data interpretation and
    • comprehensive analytical report
    • additional Post Translational Modified searches and biological interpretation (on request)

Our services are broken down as follows:

Contact us for a free initial discussion and price estimate on your project.

Contact us for an example copy of our final analysis report.

Recent news

February 3, 2026

Holding(s) in Company

TR-1: Standard form for notification of major holdings
January 28, 2026

Result of Oversubscribed Retail Offer

Proteome Sciences (AIM: PRM) is pleased to announce that the Retail Offer launched on 26 January 2026 has successfully completed and closed today at 12.00 p.m. The Retail Offer was significantly oversubscribed. Accordingly, the Company has…
January 26, 2026

Retail Offer to raise up to £60,000

Proteome Sciences (AIM: PRM) is pleased to announce the launch of an offer to retail investors in the UK through BookBuild (the "Retail Offer") of up to 3,428,571  new ordinary shares of one penny each in the capital of the Company…
January 26, 2026

£840,000 Fundraise and Retail Offer

Proteome Sciences (AIM:PRM) is pleased to announce that it has successfully raised gross proceeds of £840,000 (the “Fundraise”) through the issue of 48,000,000 ordinary shares of one penny each in the capital of the Company (the…
January 6, 2026

Two further substantial contracts for Proteome Sciences

Proteome Sciences (AIM:PRM), is pleased to announce that following the Company’s announcement dated 8 December 2025, the Company has secured two further substantial Good Clinical Laboratory Practice (“GCLP”) contracts. The contracts…
December 8, 2025

Substantial contract for Proteome Sciences

Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a third contract from a US biopharmaceutical company using the Company’s mass spectrometry services to develop a new assay at the company’s facilities in…

Recent Updates

Keep up to date with proteome sciences and learn about crucial areas about our services and scientists
Applied Proteomics

Detailed measurement of proteins from samples collected during drug development & clinical research to inform better decision making and outcomes

  • Biomarker Services Outsource partner for proteomics and biomarker assays. Significant investment in MS knowledge and instrumentation
  • Reagents for mass spectrometry Exclusive TMT licence with Thermo Scientific
  • Bioinformatics Data insights and analyses
  • Proprietary Licences / IP Portfolio of >400 patents across range of diseases and applications

Upcoming events